Search Results
Jun 25, 2026, 09:00 ET GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout -- HBSS
/PRNewswire/ -- On February 20, 2026, GRAIL, Inc. (NASDAQ: GRAL) shed over $2.2 billion of market capitalization after surprising investors with its NHS-Galleri Trial readout. The news caused huge investor losses and triggered a securities class action lawsuit seeking to represent investors who purchased
More news about: Hagens Berman Sobol Shapiro LLP
Jun 25, 2026, 09:00 ET GRAIL Completes $110 Million Equity Financing With Samsung Entities
evaluation1-3. The Galleri test is backed by a robust clinical evidence program, with more than 380,000 participants across multiple studies, including the NHS-Galleri trial, the first and only randomized controlled trial for an MCED test. The Galleri test has delivered consistent performance across these studies.
More news about: GRAIL, Inc.
Jun 25, 2026, 09:00 ET ROYAL CARIBBEAN PARTNERS WITH ROALD DAHL'S MARVELLOUS CHILDREN'S CHARITY AHEAD OF "CHARLIE AND THE CHOCOLATE FACTORY" DEBUT ON LEGEND OF THE SEAS
fundraising moments across Legend's inaugural European season will help support the charity's network of more than 250 specialist nurses working across NHS Trusts, delivering coordinated care alongside emotional and financial support to families. "As a brand focused on creating memorable holidays
More news about: Royal Caribbean International
Jun 25, 2026, 07:10 ET GRAL INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
significant reduction in Stage III-IV cancers in Grail's NHS-Galleri trial, while also concealing material adverse facts which reduced the possibility of such an outcome; (ii) in truth, Grail's optimism in achieving the primary endpoint of its NHS-Galleri study fell short of reality; and (iii) the confidence
More news about: Robbins Geller Rudman & Dowd LLP
Jun 24, 2026, 19:14 ET Robbins LLP Urges GRAL Stockholders Who Lost Money Investing in Grail, Inc. to Contact the Firm for Information About Leading the Class Action
February 19, 2026What are the Allegations? Robbins LLP is Investigating Allegations that Grail, Inc. (GRAL) Misled Investors Concerning NHS-Galleri's Potential to Achieve statistically significant reduction in Stage III-IV cancersFor more information, submit a
More news about: Robbins LLP
Jun 24, 2026, 10:07 ET Lost Money on Grail, Inc. (GRAL)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
disclosed its NHS-Galleri trial failed to achieve its primary endpoint. Investors have until August 4, 2026 to seek lead plaintiff appointment.The Early OptimismIn May 2025, Grail announced positive top-line results from the prevalent screening round of its 140,000-participant NHS-Galleri
More news about: Levi & Korsinsky, LLP
Jun 23, 2026, 16:00 ET GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit
the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of GRAIL's NHS-Galleri trial following the reveal of the top-line results covering the first screening round. Notably, as defendants have since attested, the trial
More news about: THE ROSEN LAW FIRM, P. A.
Jun 23, 2026, 10:00 ET GRAL UPCOMING DEADLINE : The Gross Law Firm Alerts GRAIL, Inc. Stockholders of Securities Class Action - Contact the Firm
the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of GRAIL's NHS-Galleri trial following the reveal of the top-line results covering the first screening round. Notably, as defendants have since attested, the trial
More news about: The Gross Law Firm
Jun 23, 2026, 06:50 ET GRAL Class Notice: GRAIL, Inc. Investors that Suffered Losses are Notified of the Imminent August 4 Securities Class Action Deadline
implementation of its test as a national screening program through the United Kingdom's National Health Service ("NHS"), GRAIL conducted the "NHS-Galleri trial." The primary objective of the NHS-Galleri trial was "to show a reduction in late-stage (III-IV) cancers in people who received the Galleri test
More news about: Bleichmar Fonti & Auld LLP
Jun 18, 2026, 18:56 ET GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit
the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of GRAIL's NHS-Galleri trial following the reveal of the top-line results covering the first screening round. Notably, as defendants have since attested, the trial
More news about: THE ROSEN LAW FIRM, P. A.
Jun 18, 2026, 10:07 ET GRAL Shareholder Alert: Grail, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt
promoted the NHS-Galleri readout as a "great calling card" for global expansion and described the upcoming clinical utility data as a key catalystOn October 20, 2025, management stated that PATHFINDER 2 results gave them "a lot of confidence in the performance" heading into the NHS-Galleri readoutThe
More news about: SueWallSt.com
Jun 18, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GRAIL, Inc. of Class Action Lawsuit and Upcoming Deadlines - GRAL
action] On February 19, 2026, Grail announced that "primary endpoint of statistically significant Stage III-IV reduction was not observed" in the NHS-Galleri Trial. Grail attributed this shortcoming, in part, to "probably need[ing] a longer follow-up time to be able to [compare the study arms] adequately." On
More news about: Pomerantz LLP
Jun 17, 2026, 10:13 ET GRAL DEADLINE: Levi & Korsinsky Reminds Grail, Inc. Investors of Upcoming Securities Class Action Deadline
Time-Sensitive: Allegations Focus on Defendants' Refusal to Share Detailed NHS-Galleri Data, Potentially Concealing Adverse Trendlines From InvestorsNEW YORK, June 17, 2026 /PRNewswire/ -- Levi & Korsinsky,
More news about: Levi & Korsinsky, LLP
Jun 17, 2026, 06:28 ET Phase 1 MRX1 Study Delivers Strong Headline Data
PharmaAnanda Pharma is a UK pharmaceutical company providing its MRX1 oral solution to two Phase 2 clinical trials: ENDOCAN (endometriosis pain, funded by NHS Scotland) and ACTION (CIPN, funded by an NIHR EME grant). The Company works with world-class scientists, including Key Opinion Leaders at the University
More news about: Ananda Pharma Limited
Jun 16, 2026, 10:01 ET PD-L1 Biomarker Testing Market to Reach USD 1,830.7 Million by 2036 as Precision Oncology and Immunotherapy Adoption Accelerate Global Demand
Opportunity AssessmentUnited KingdomThe UK is projected to record the fastest growth at 9.3% CAGR through 2036, driven by NHS modernization, healthcare digitalization, and increased biomarker testing adoption.JapanJapan is expected to grow at 9.1% CAGR,
More news about: Future Market Insights
Jun 16, 2026, 09:13 ET GRAL DEADLINE: The Gross Law Firm Reminds GRAIL, Inc. Investors of Upcoming Securities Class Action Deadline
the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of GRAIL's NHS-Galleri trial following the reveal of the top-line results covering the first screening round. Notably, as defendants have since attested, the trial
More news about: The Gross Law Firm
Jun 16, 2026, 06:07 ET GRAL Court Deadline: GRAIL, Inc. Investors are Notified of the Important August 4 Deadline in the Pending Securities Fraud Class Action Lawsuit
implementation of its test as a national screening program through the United Kingdom's National Health Service ("NHS"), GRAIL conducted the "NHS-Galleri trial." The primary objective of the NHS-Galleri trial was "to show a reduction in late-stage (III-IV) cancers in people who received the Galleri test
More news about: Bleichmar Fonti & Auld LLP
Jun 15, 2026, 20:33 ET GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit
the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of GRAIL's NHS-Galleri trial following the reveal of the top-line results covering the first screening round. Notably, as defendants have since attested, the trial
More news about: THE ROSEN LAW FIRM, P. A.
Jun 15, 2026, 19:01 ET The AI from Skin Analytics that caught 20,000 cancers in the UK is now certified for use on a standard smartphone
from a standard smartphone, built on the same Class III regulated AI that has been deployed across NHS skin cancer pathways for six years. DERM, the AI platform that powers DERM Zero, is used across 24 NHS hospitals, has assessed more than 230,000 patients and detected more than 20,000 cancers
More news about: Skin Analytics
Jun 15, 2026, 19:01 ET L'IA qui a détecté 20 000 cas de cancer au Royaume-Uni est désormais certifiée pour une utilisation sur un smartphone
classe III qui est déployée depuis six ans dans les protocoles de prise en charge du cancer de la peau du NHS. DERM, la plateforme IA qui alimente DERM Zero, est utilisée dans 24 hôpitaux du NHS, a évalué plus de 230 000 patients et détecté plus de 20 000 cancersAMSTERDAM,
More news about: Skin Analytics
Jun 15, 2026, 19:01 ET La IA que ha detectado 20.000 cánceres en Reino Unido ya está certificada para usarse en smartphone1
para la detección de cáncer de piel en el Sistema Nacional Público de Salud del Reino Unido (NHS - National Health Service). DERM, la IA como dispositivo médico detrás de DERM Zero, se usa en 24 hospitales del NHS, y ha evaluado a más de 230.000 pacientes y ha detectado más de 20.000 cánceres de piel.
More news about: Skin Analytics
Jun 15, 2026, 17:58 ET 美納里尼集團於 2026 年歐洲血液學協會 (EHA) 年會公佈 Selinexor 聯合 Ruxolitinib 治療骨髓纖維化的第 3 期 SENTRY 試驗數據
* 分析涵蓋已完成脾臟評估或於第 36 週前退出研究的患者Guy's and St. Thomas' NHS Foundation Trust 骨髓增殖性腫瘤學教授兼副首席醫療總監 Claire Harrison 博士表示：「實現脾臟縮小是骨髓纖維化治療的核心目標。 值得注意的是，SENTRY 試驗所顯示的脾臟縮小效果不但起效迅速，而且幅度顯著且持久，並與接受聯合治療患者的潛在總存活期獲益相關， 我們對這些結果感到鼓舞，因為這代表有望為迫切需要更佳治療選擇的患者帶來新的治療進展。」其他重點結果包括：
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 15, 2026, 16:44 ET Le Groupe Menarini présente les résultats de l'essai clinique SENTRY de phase III sur l'association selinexor-ruxolitinib dans le traitement de la myélofibrose lors du congrès 2026 de l'Association européenne d'hématologie (EHA)
traitement combiné », déclare le Dr Claire Harrison, professeure en néoplasmes myéloprolifératifs et médecin-chef adjointe au Guy's and St. Thomas' NHS Foundation Trust. « Nous sommes encouragés par le fait que ces résultats constituent une avancée thérapeutique potentielle pour nos patients, qui ont
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 15, 2026, 16:10 ET Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period
(PATH):Long-Term Reductions in Hyperphagia: HQ-CT AnalysisA poster presentation led by Evelien F. Gevers, M.D., Ph.D., Barts Health NHS Trust/Queen Mary University of London, reported three-year data comparing 125 VYKAT XR-treated participants from Studies C601 and C602-OLE to 229 natural
More news about: Neurocrine Biosciences, Inc.
Jun 15, 2026, 09:30 ET GRAL INVESTOR NOTICE: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
significant reduction in Stage III-IV cancers in Grail's NHS-Galleri trial, while also concealing material adverse facts which reduced the possibility of such an outcome; (ii) in truth, Grail's optimism in achieving the primary endpoint of its NHS-Galleri study fell short of reality; and (iii) the confidence
More news about: Robbins Geller Rudman & Dowd LLP